Citations

Clear

9383 citation(s) found for "Thomas, PS".

Stratification of Breast Cancer Risk in Women With Atypia: A Mayo Cohort Study
Visscher, Daniel W., Berman, Hal K. , Frost, Marlene H., Sellers, Thomas A. , Vierkant, Robert A. , Maloney, Shaun D., Groen, Piet C. de , Lingle, Wilma L., Ghosh, Karthik, Penheiter, Lois, Tlsty, Thea D. , Melton, L. Joseph , Reynolds, Carol, Hartmann, Lynn C. , Degnim, Amy C. , Pankratz, V. Shane , Vierkant, Robert A

Mayo Clinic

Journal of Clinical Oncology | June 12, 2007 | Volume: 25 | Issue: 19 | Pages: 2671-2677

10.1200/jco.2006.09.0217 | PMID 17563394 Get It

Purpose Atypical hyperplasia is a well-recognized risk factor for breast cancer, conveying an approximately four-fold increased risk. Data regarding long-term absolute risk and factors for risk stratification are needed. Patients and Methods Women with atypical hyperplasia in the Mayo Benign Breast Disease Cohort were identified through pathology review. Subsequent breast cancers were identified via medical records and a questionnaire. Relative risks (RRs) were estimated using standardized incidence ratios, comparing the observed number of breast cancers with those expected based on Iowa Surveillance, Epidemiology, and End Results (SEER) data. Age, histologic factors, and family history were evaluated as risk modifiers. Plots of cumulative breast cancer incidence provided estimates of risk over time. Results With mean follow-up of 13.7 years, 66 breast cancers (19.9%) occurred among 331 women with atypia. RR of breast cancer with atypia was 3.88 (95% CI, 3.00 to 4.94). Marked elevations in risk were seen with multifocal atypia (eg, three or more foci with calcifications [RR, 10.35; 95% CI, 6.13 to 16.4]). RR was higher for younger women (< 45; RR, 6.76; 95% CI, 3.24 to 12.4). Risk was similar for atypical ductal and atypical lobular hyperplasia, and family history added no significant risk. Breast cancer risk remained elevated over 20 years, and the cumulative incidence approached 35% at 30 years. Conclusion Among women with atypical hyperplasia, multiple foci of atypia and the presence of histologic calcifications may indicate “very high risk” status (> 50% risk at 20 years). A positive family history does not further increase risk in women with atypia.
Phase III Study of Capecitabine Plus Oxaliplatin Compared With Fluorouracil and Leucovorin Plus Oxaliplatin in Metastatic Colorectal Cancer: A Final Report of the AIO Colorectal Study Group
Porschen, Rainer, Arkenau, Hendrik‐Tobias , Kubicka, S., Greil, Richard , Seufferlein, Thomas , Freier, Werner , Kretzschmar, Albrecht , Hinke, Axel , Schmiegel, Wolff , Graeven, Ullrich , Grothey, Axel , Schmoll, Hans‐Joachim

Mayo Clinic

Journal of Clinical Oncology | June 5, 2007 | Volume: 25 | Issue: 27 | Pages: 4217-4223

10.1200/jco.2006.09.2684 | PMID 17548840 Get It

Purpose To compare the use of capecitabine plus oxaliplatin (CAPOX) with infusional fluorouracil (FU)/folinic acid plus oxaliplatin (FUFOX) as first-line therapy for patients with metastatic colorectal cancer (MCRC). Patients and Methods A total of 474 patients with MCRC received either CAPOX (capecitabine 1,000 mg/m2 bid, days 1 to 14 plus oxaliplatin 70 mg/m2 days 1 and 8, repeated every 22 days) ) or FUFOX (oxaliplatin 50 mg/m2 followed by leucovorin 500 mg/m2 plus FU 2,000 mg/m2 as a 22-hour infusion days 1, 8, 15, and 22, repeated every 36 days). The primary end point was progression-free survival (PFS). Secondary end points were response rate (RR), overall survival (OS), time to treatment failure, and toxicity. The study was designed to determine noninferiority for the CAPOX regimen. Results Median PFS was 7.1 months in the CAPOX arm and 8.0 months in the FUFOX arm (hazard ratio [HR], 1.17; 95% CI, 0.96 to 1.43; P = .117). Median OS was 16.8 months (CAPOX) and 18.8 months (FUFOX; HR, 1.12; 95% CI, 0.92 to 1.38; P = .26). Overall RRs were 48% for CAPOX (95% CI, 41% to 54%) and 54% for FUFOX (95% CI, 47% to 60%). Both regimens were generally well tolerated, although there was a significantly higher incidence of grade 2/3 hand-foot syndrome (HFS) in the CAPOX arm (P = .028). Conclusion CAPOX resulted in a slightly inferior efficacy than FUFOX. With respect to PFS, the best estimate of the HR of 1.17 was within the prespecified equivalence range. However, a relevant inferiority cannot be excluded. Both regimens were generally well tolerated but there was a significantly higher rate of grade 2/3 HFS in the CAPOX arm.
S2–01–01: Role of vascular risk factors in cognitive decline beginning in middle age
Coker, Laura H., Knopman, David S. , Catellier, Diane , Mosley, Thomas H.

Mayo Clinic

Alzheimer's & Dementia | June 4, 2007 | Volume: 3 | Issue: 3S_Part_3 | Pages: No page available

10.1016/j.jalz.2007.04.059 Get It

O2–03–03: Selective T1‐weighted enhancement of individual Alzheimer's disease amyloid plaques using an antibody fragment against Aβ42 as a magnetic resonance molecular imaging contrast agent
Poduslo, Joseph F., Ramakrishnan, Muthu, Wengenack, Thomas M., Curran, Geoffry L., Gilles, Emily J., Kandimalla, Karunya K. , Ramı́rez-Alvarado, Marina , Garwood, Michael , Jack, Clifford R.

Mayo Clinic

Alzheimer's & Dementia | June 4, 2007 | Volume: 3 | Issue: 3S_Part_3 | Pages: No page available

10.1016/j.jalz.2007.04.028 Get It

Association of Integrin α2 Gene Variants with Ischemic Stroke
Matarín, Mar, Brown, W. Mark , Hardy, John , Rich, Stephen S. , Singleton, Andrew , Brown, Robert D., Brott, Thomas G. , Worrall, Bradford B. , ISGS, SWISS, Groups, MSGD Study, Meschia, James F. , ISGS, SWISS, Groups, MSGD Study, Rich, Stephen S , Hardy, John

Mayo Clinic

Journal of Cerebral Blood Flow & Metabolism | May 30, 2007 | Volume: 28 | Issue: 1 | Pages: 81-89

10.1038/sj.jcbfm.9600508 | PMID 17534386 Get It

Genetic variants in the gene encoding integrin α2 ( ITGA2) have been reported to be associated with an increased risk for ischemic stroke. The purpose of this study was to investigate the association between haplotype-tagging single-nucleotide polymorphisms (tSNPs) in ITGA2 and risk of ischemic stroke in a collection of North American stroke cases and controls. The study included 484 cases and 263 controls. Thirteen tSNPs were genotyped. Association tests at and across each tSNP were performed, including haplotype association analysis. Secondary analyses considered stroke subtypes on the basis of Trial of Org 10172 in Acute Stroke Treatment (TOAST) criteria. We observed significant association between tSNP rs3756541 (additive model, odds ratio (OR), 1.49; 95% confidence interval (CI), 1.11 to 2.04; P = 0.009) and disease and a trend toward association at rs2303124 (recessive model, OR, 1.56; 95% CI, 1.05 to 2.33; P = 0.03). These associations remained significant in the haplotype analyses. The associated tSNPs did not distinguish stroke etiology after application of TOAST criteria. Our results suggest that genetic variability within ITGA2 may confer risk for ischemic stroke independent of conventional risk factors. These results provide additional support for a role for platelet receptor genes in the pathogenesis of ischemic stroke of diverse subtypes.
Targeted Diagnostics and Therapeutics for Individualized Patient Management
Waldman, Scott A. , Terzic, André

Mayo Clinic

Biomarkers in Medicine | May 25, 2007 | Volume: 1 | Issue: 1 | Pages: 3-8

10.2217/17520363.1.1.3 | PMID 20477454 Get It

Phase I/II Study of an Anti-CD30 Monoclonal Antibody (MDX-060) in Hodgkin's Lymphoma and Anaplastic Large-Cell Lymphoma
Ansell, Stephen M. , Engert, Andreas , Khan, Khuda Dad, Lin, Thomas S., Strair, Roger , Keler, Tibor , Graziano, Robert F., Blanset, Diann, Yellin, Michael , Fischkoff, Steven, Assad, Albert , Borchmann, Peter , Horwitz, Steven M.

Mayo Clinic

Journal of Clinical Oncology | May 22, 2007 | Volume: 25 | Issue: 19 | Pages: 2764-2769

10.1200/jco.2006.07.8972 | PMID 17515574 Get It

Purpose MDX-060 is a human anti-CD30 immunoglobulin (Ig) G1κ monoclonal antibody that inhibits growth of CD30-expressing tumor cells in preclinical models. To determine the safety, maximum-tolerated dose (MTD), and efficacy of MDX-060 in patients with relapsed or refractory CD30+ lymphomas, sequential phase I and II studies were performed. Patients and Methods In the phase I portion, MDX-060 was administered intravenously at doses of 0.1, 1, 5, or 10 mg/kg weekly for 4 weeks to cohorts of three to six patients. Twenty-one patients—16 with Hodgkin's lymphoma (HL), three with anaplastic large-cell lymphoma (ALCL), and two with CD30+ T-cell lymphoma—were enrolled. Because of the lack of a defined MTD or dose-response correlation, the phase II portion was amended to include several dose levels. In the phase II portion, an additional 51 patients, 47 with HL and four with ALCL, were treated at doses of 1, 5, 10, and 15 mg/kg. Results MDX-060 was well tolerated, and an MTD has not been identified. Only 7% of patients experienced grade 3 or 4 treatment-related adverse events. Among the 72 patients treated, clinical responses were observed in six. Twenty-five patients had stable disease, including five who remained free from progression 1 year after treatment. Conclusion MDX-060 was well tolerated at doses up to 15 mg/kg. MDX-060 has limited activity as a single agent, but the minimal toxicity observed and the significant proportion of patients with stable disease suggests that further study of MDX-060 in combination with other therapies is warranted.
Predicting the Outcome of Salvage Radiation Therapy for Recurrent Prostate Cancer After Radical Prostatectomy
Stephenson, Andrew J. , Scardino, Peter T. , Kattan, Michael W. , Pisansky, Thomas M. , Slawin, Kevin M., Klein, Eric A. , Anscher, Mitchell S. , Michalski, Jeff M. , Lin, Daniel W. , Forman, Jeffrey D., Zeléfsky, Michael J. , Kestin, Larry L. , Roehrborn, Claus G. , Catton, Charles , DeWeese, Theodore L. , Liauw, Stanley L. , Valicenti, Richard K., Kuban, Deborah A., Pollack, Alan , Sandler, Howard M. , Klein, Eric A , Liauw, Stanley L , Kattan, Michael W

Mayo Clinic

Journal of Clinical Oncology | May 19, 2007 | Volume: 25 | Issue: 15 | Pages: 2035-2041

10.1200/jco.2006.08.9607 | PMID 17513807 Get It

Purpose An increasing serum prostate-specific antigen (PSA) level is the initial sign of recurrent prostate cancer among patients treated with radical prostatectomy. Salvage radiation therapy (SRT) may eradicate locally recurrent cancer, but studies to distinguish local from systemic recurrence lack adequate sensitivity and specificity. We developed a nomogram to predict the probability of cancer control at 6 years after SRT for PSA-defined recurrence. Patients and Methods Using multivariable Cox regression analysis, we constructed a model to predict the probability of disease progression after SRT in a multi-institutional cohort of 1,540 patients. Results The 6-year progression-free probability was 32% (95% CI, 28% to 35%) overall. Forty-eight percent (95% CI, 40% to 56%) of patients treated with SRT alone at PSA levels of 0.50 ng/mL or lower were disease free at 6 years, including 41% (95% CI, 31% to 51%) who also had a PSA doubling time of 10 months or less or poorly differentiated (Gleason grade 8 to 10) cancer. Significant variables in the model were PSA level before SRT (P < .001), prostatectomy Gleason grade (P < .001), PSA doubling time (P < .001), surgical margins (P < .001), androgen-deprivation therapy before or during SRT (P < .001), and lymph node metastasis (P = .019). The resultant nomogram was internally validated and had a concordance index of 0.69. Conclusion Nearly half of patients with recurrent prostate cancer after radical prostatectomy have a long-term PSA response to SRT when treatment is administered at the earliest sign of recurrence. The nomogram we developed predicts the outcome of SRT and should prove valuable for medical decision making for patients with a rising PSA level.
A Combined, Minimally Invasive Transnasal Approach to the Sella Turcica
Nasseri, Shawn S., McCaffrey, Thomas V., Kasperbauer, Jan L. , Atkinson, John L. D.

Mayo Clinic

American Journal of Rhinology | May 16, 2007 | Volume: 12 | Issue: 6 | Pages: 409-416

10.2500/105065898780707883 | PMID 9883297 Get It

The increasing use of endonasal techniques and a new 3-dimensional CT-guided imaging system have allowed us to develop a combined, minimally invasive endonasal approach to the pituitary gland. Thus far, more than 30 patients have undergone an endonasal transsphenoidal approach to the sella using a combined endoscopic approach, with additional selective use of the Instatrak CT-guided imaging system for realtime imaging. Our current technique involves obtaining a preoperative CT using a plastic head frame with registration markers. By using this head frame intraoperatively, real-time localization with CT images in axial, coronal, and sagittal planes can be performed. Using endoscopic techniques and a Papavero-Caspar speculum, the sella is exposed. A combined approach using endoscopes, the operating microscope, and real-time localization is undertaken to expose and resect tumors. We have encountered minimal associated complications in our series, and this method has been progressively modified to improve exposure and safety. Because we are able to visualize the sella without a sublabial incision or septal resection, we have nearly eliminated the need for nasal packing, reduced the average hospital stay to 2.5 days, and improved patient satisfaction.
Longitudinal Trends in Mammographic Percent Density and Breast Cancer Risk
Vachon, Celine M. , Scott, Christopher G. , Maloney, Shaun D., Ghosh, Karthik, Brandt, Kathleen R. , Milanese, Tia R., Carston, Michael J., Sellers, Thomas A. , Vachon, Celine M. , Pankratz, V. Shane , Scott, Christopher

Mayo Clinic

Cancer Epidemiology, Biomarkers & Prevention | May 16, 2007 | Volume: 16 | Issue: 5 | Pages: 921-928

10.1158/1055-9965.epi-06-1047 | PMID 17507617 Get It

Abstract Background: Mammographic density is a strong risk factor for breast cancer. However, whether changes in mammographic density are associated with risk remains unclear. Materials and Methods: A study of 372 incident breast cancer cases and 713 matched controls was conducted within the Mayo Clinic mammography screening practice. Controls were matched on age, exam date, residence, menopause, interval between, and number of mammograms. All serial craniocaudal mammograms 10 years before ascertainment were digitized, and quantitative measures of percent density (PD) were estimated using a thresholding method. Data on potential confounders were abstracted from medical records. Logistic regression models with generalized estimating equations were used to evaluate the interactions among PD at earliest mammogram, time from earliest to each serial mammogram, and absolute change in PD between the earliest and subsequent mammograms. Analyses were done separately for PD measures from the ipsilateral and contralateral breast and also by use of hormone therapy (HT). Results: Subjects had an average of five mammograms available, were primarily postmenopausal (83%), and averaged 61 years at the earliest mammogram. Mean PD at earliest mammogram was higher for cases (31%) than controls (27%; ipsilateral side). There was no evidence of an association between change in PD and breast cancer risk by time. Compared with no change, an overall reduction of 10% PD (lowest quartile of change) was associated with an odds ratio of 0.9997 and an increase of 6.5% PD (highest quartile of change) with an odds ratio of 1.002. The same results held within the group of 220 cases and 340 controls never using HT. Among the 124 cases and 337 controls known to use HT during the interval, there was a statistically significant interaction between change in PD and time since the earliest mammogram (P = 0.01). However, in all groups, the risk associated with the earliest PD remained a stronger predictor of risk than change in PD. Conclusion: We observed no association between change in PD with breast cancer risk among all women and those never using HT. However, the interaction between change in PD and time should be evaluated in other populations. (Cancer Epidemiol Biomarkers Prev 2007;16(5):921–8)